The U.S. FDA had inspected the API facility, in Mekaguda here, from June 9-13 and issued Form 483 with one observation. The regulator had classified it as “voluntary action indicated” (VAI), the ...

In a regulatory filing made during market hours today, Natco Pharma announced that it has received an establishment ...

Q1FY26 revenues at ?12.7 billion, YoY growth of 142% and flat QoQ growth. This includes revenues from the acquired NRT business.